Levi Alexander Garraway
#121,238
Most Influential Person Now
Levi Alexander Garraway's AcademicInfluence.com Rankings
Levi Alexander Garrawaymedical Degrees
Medical
#1853
World Rank
#2231
Historical Rank
Pharmacology
#177
World Rank
#216
Historical Rank

Levi Alexander Garrawayphilosophy Degrees
Philosophy
#5502
World Rank
#8323
Historical Rank
Logic
#2770
World Rank
#3807
Historical Rank

Download Badge
Medical Philosophy
Levi Alexander Garraway's Degrees
- Doctorate Medicine Harvard University
Why Is Levi Alexander Garraway Influential?
(Suggest an Edit or Addition)Levi Alexander Garraway's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity (2012) (6062)
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways (2008) (5775)
- Comprehensive molecular profiling of lung adenocarcinoma (2014) (4095)
- The landscape of somatic copy-number alteration across human cancers (2010) (3297)
- Mutational heterogeneity in cancer and the search for new cancer-associated genes (2013) (2852)
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq (2016) (2825)
- Mutational heterogeneity in cancer and the search for new cancer genes (2013) (2691)
- Discovery and saturation analysis of cancer genes across 21 tumor types (2014) (2530)
- Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (2458)
- The Mutational Landscape of Head and Neck Squamous Cell Carcinoma (2011) (2301)
- A Landscape of Driver Mutations in Melanoma (2012) (2244)
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade (2016) (2221)
- Genomic Classification of Cutaneous Melanoma (2015) (2143)
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden (2017) (2129)
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma (2015) (2032)
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014) (2007)
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing (2012) (1620)
- Next-generation characterization of the Cancer Cell Line Encyclopedia (2019) (1561)
- Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma (2005) (1458)
- Initial genome sequencing and analysis of multiple myeloma (2011) (1385)
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer (2012) (1367)
- BRAF mutation predicts sensitivity to MEK inhibition (2006) (1323)
- Defining a Cancer Dependency Map (2017) (1307)
- The genomic complexity of primary human prostate cancer (2010) (1195)
- Lessons from the Cancer Genome (2013) (1147)
- Sequence analysis of mutations and translocations across breast cancer subtypes (2012) (1133)
- Characterizing the cancer genome in lung adenocarcinoma (2007) (1122)
- Punctuated Evolution of Prostate Cancer Genomes (2013) (1105)
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. (2016) (1060)
- Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma (2007) (1052)
- High-throughput oncogene mutation profiling in human cancer (2007) (1041)
- Divergent clonal evolution of castration resistant neuroendocrine prostate cancer (2016) (1032)
- Recurrent BRAF mutations in Langerhans cell histiocytosis. (2010) (948)
- Highly Recurrent TERT Promoter Mutations in Human Melanoma (2013) (948)
- Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. (2011) (938)
- COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation (2010) (778)
- The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. (2014) (769)
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. (2015) (727)
- Melanoma genome sequencing reveals frequent PREX2 mutations (2012) (695)
- Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy (2010) (653)
- p63 is a prostate basal cell marker and is required for prostate development. (2000) (629)
- MEK1 mutations confer resistance to MEK and B-RAF inhibition (2009) (616)
- Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis (2015) (616)
- Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene (2007) (613)
- An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules (2013) (533)
- The long tail of oncogenic drivers in prostate cancer (2018) (529)
- Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. (2013) (515)
- AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. (2009) (510)
- Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer (2013) (506)
- PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. (2009) (495)
- Malignant melanoma: genetics and therapeutics in the genomic era. (2006) (493)
- Functional genomics reveal that the serine synthesis pathway is essential in breast cancer (2011) (491)
- Melanoma: from mutations to medicine. (2012) (479)
- High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. (2012) (478)
- An Integrated Approach to Uncover Drivers of Cancer (2010) (472)
- The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset (2011) (471)
- Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors (2017) (469)
- Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (445)
- Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples (2009) (439)
- Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. (2016) (436)
- MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. (2014) (430)
- Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. (2015) (423)
- Circumventing cancer drug resistance in the era of personalized medicine. (2012) (415)
- A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. (2014) (412)
- Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer (2011) (412)
- Quantitative Proteomics of the Cancer Cell Line Encyclopedia (2020) (406)
- A melanocyte lineage program confers resistance to MAP kinase pathway inhibition (2013) (403)
- Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma (2016) (396)
- Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (383)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2019) (376)
- RNF43 is frequently mutated in colorectal and endometrial cancers (2014) (371)
- Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing (2006) (354)
- Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma (2016) (353)
- Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. (2005) (341)
- Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine (2014) (339)
- Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. (2018) (337)
- Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma (2014) (335)
- Lineage dependency and lineage-survival oncogenes in human cancer (2006) (326)
- A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. (2013) (316)
- ARID1B is a specific vulnerability in ARID1A-mutant cancers (2014) (312)
- Genomics-driven oncology: framework for an emerging paradigm. (2013) (308)
- Pharmacogenomic agreement between two cancer cell line data sets (2015) (306)
- Genetic Mechanisms of Immune Evasion in Colorectal Cancer. (2018) (305)
- Institutional implementation of clinical tumor profiling on an unselected cancer population. (2016) (303)
- Precision oncology: an overview. (2013) (302)
- MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells (2016) (301)
- Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion (2011) (298)
- RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. (2012) (298)
- Modeling genomic diversity and tumor dependency in malignant melanoma. (2008) (294)
- Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. (2018) (294)
- Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. (2014) (289)
- Integrative analysis of the melanoma transcriptome. (2010) (288)
- The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts (2003) (278)
- Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine (2013) (275)
- Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. (2009) (275)
- Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation (2009) (274)
- The landscape of cancer cell line metabolism (2019) (273)
- A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma (2014) (269)
- Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. (2010) (267)
- Response and acquired resistance to everolimus in anaplastic thyroid cancer. (2014) (264)
- Assessing the clinical utility of cancer genomic and proteomic data across tumor types (2014) (262)
- Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. (2014) (262)
- Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. (2012) (254)
- Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. (2015) (240)
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. (2015) (239)
- Synthetic lethality as an engine for cancer drug target discovery (2019) (216)
- Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia (2013) (214)
- Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location (2016) (211)
- Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. (2018) (209)
- BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition (2013) (207)
- Evidence that the vectorial competence of phlebotomine sand flies for different species of Leishmania is controlled by structural polymorphisms in the surface lipophosphoglycan. (1994) (206)
- Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4 (2017) (202)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Clinical implications of the cancer genome. (2010) (195)
- Functional genomics reveals serine synthesis is essential in PHGDH-amplified breast cancer (2011) (195)
- TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. (2016) (195)
- Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts (2009) (189)
- Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. (2016) (188)
- Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. (2007) (184)
- Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer (2014) (184)
- A single-cell landscape of high-grade serous ovarian cancer (2020) (184)
- Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones. (1991) (177)
- Inferring Loss-of-Heterozygosity from Unpaired Tumors Using High-Density Oligonucleotide SNP Arrays (2006) (177)
- Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state (2017) (173)
- High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines (2016) (172)
- Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery (2010) (167)
- A Convergence-Based Framework for Cancer Drug Resistance. (2018) (153)
- A functional landscape of resistance to ALK inhibition in lung cancer. (2015) (151)
- Nuclear factor I/B is an oncogene in small cell lung cancer. (2011) (147)
- Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. (2016) (143)
- The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine (2016) (136)
- Metabolomic adaptations and correlates of survival to immune checkpoint blockade (2019) (130)
- IFNγ-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment (2017) (129)
- Future cancer research priorities in the USA: a Lancet Oncology Commission. (2017) (125)
- ATARiS: Computational quantification of gene suppression phenotypes from multisample RNAi screens (2013) (124)
- AKT signaling in physiology and disease. (2010) (121)
- gkmSVM: an R package for gapped-kmer SVM (2016) (120)
- Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair (2013) (120)
- Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity (2018) (117)
- Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors (2017) (117)
- Isolation of virulence genes directing surface glycosyl-phosphatidylinositol synthesis by functional complementation of Leishmania. (1993) (116)
- An oncogenic role for ETV1 in melanoma. (2010) (116)
- A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns (2020) (113)
- Intermediate basal cells of the prostate: In vitro and in vivo characterization (2003) (113)
- Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. (2016) (110)
- Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. (2005) (107)
- Erratum: Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma (Cell Reports (2016) 15(4) (857–865) (S2211124716303643) (10.1016/j.celrep.2016.03.075)) (2016) (106)
- p85 Associates with Unphosphorylated PTEN and the PTEN-Associated Complex (2009) (102)
- Oncologists' and Cancer Patients' Views on Whole-Exome Sequencing and Incidental Findings: Results from The CanSeq Study (2016) (101)
- Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection (2014) (101)
- Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants. (2016) (100)
- Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium (2013) (99)
- Attitudes of patients with cancer about personalized medicine and somatic genetic testing. (2012) (97)
- Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade (2018) (97)
- Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation (2015) (97)
- Unraveling the clonal hierarchy of somatic genomic aberrations (2014) (92)
- Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. (2017) (91)
- Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set (2010) (90)
- Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. (2016) (90)
- Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer (2014) (90)
- ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. (2014) (87)
- Characterizing genomic alterations in cancer by complementary functional associations (2016) (86)
- Androgen-dependent regulation of Her-2/neu in prostate cancer cells. (2006) (86)
- The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer (2019) (85)
- Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer (2017) (84)
- High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. (2011) (83)
- FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder (2014) (81)
- Epigenomic alterations in localized and advanced prostate cancer. (2013) (80)
- Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. (2011) (79)
- Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance (2017) (77)
- The SETDB1 histone methyltransferase is recurrently amplified in and accelerates melanoma (2011) (75)
- Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors (2012) (74)
- Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. (2013) (73)
- Prospective enterprise-level molecular genotyping of a cohort of cancer patients. (2014) (73)
- Inherited DNA Repair Defects in Colorectal Cancer (2018) (73)
- Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1 (2014) (72)
- A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record (2013) (72)
- TERT promoter mutations and monoallelic activation of TERT in cancer (2015) (72)
- Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. (2016) (69)
- Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation (2015) (64)
- SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines (2008) (64)
- Rapid Intraoperative Molecular Characterization of Glioma. (2015) (64)
- High‐throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide‐3‐kinase and other oncogenes (2012) (63)
- Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. (2018) (62)
- Oncogenic Activating Mutations Are Associated with Local Copy Gain (2009) (62)
- A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas (2017) (60)
- A 2‐Mb critical region implicated in the microcephaly associated with terminal 1q deletion syndrome (2007) (60)
- The genomic landscape of prostate cancer (2012) (58)
- Erratum: Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing (2006) (58)
- Long-term drug administration in the adult zebrafish using oral gavage for cancer preclinical studies (2016) (57)
- Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors (2015) (55)
- The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. (2020) (53)
- TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas (2018) (51)
- MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas. (2019) (50)
- PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. (2015) (49)
- Genetic modifiers of EGFR dependence in non-small cell lung cancer (2014) (48)
- High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. (2012) (47)
- Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. (2015) (47)
- 22 The Cancer Cell Line Encyclopedia - Using Preclinical Models to Predict Anticancer Drug Sensitivity (2012) (46)
- Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers (2016) (44)
- A Small Molecule That Binds and Inhibits the ETV1 Transcription Factor Oncoprotein (2014) (43)
- Integrated genetic and pharmacologic interrogation of rare cancers (2016) (43)
- Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study (2017) (42)
- MicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response in Melanoma (2012) (42)
- Major copy proportion analysis of tumor samples using SNP arrays (2008) (42)
- Sex differences in oncogenic mutational processes (2019) (41)
- Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. (2016) (39)
- Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival (2020) (38)
- Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses (2021) (37)
- "Lineage addiction" in human cancer: lessons from integrated genomics. (2005) (36)
- Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma (2016) (36)
- Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. (2012) (36)
- C-RAF mutations confer resistance to RAF inhibitors. (2013) (34)
- PTR1-dependent synthesis of tetrahydrobiopterin contributes to oxidant susceptibility in the trypanosomatid protozoan parasite Leishmania major (2009) (33)
- Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. (2017) (33)
- Colorectal Cancers from Distinct Ancestral Populations Show Variations in BRAF Mutation Frequency (2013) (33)
- Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy (2013) (32)
- Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. (2016) (31)
- Frequent Mutation of the PI 3 K Pathway in Head and Neck Cancer Defi nes Predictive Biomarkers (2013) (29)
- Applications of genomics in melanoma oncogene discovery. (2009) (29)
- Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). (2018) (28)
- High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells. (2016) (27)
- MDR1 inhibition: less resistance or less relevance? (2002) (27)
- Characterizing reduced coverage regions through comparison of exome and genome sequencing data across ten centers (2017) (26)
- From integrated genomics to tumor lineage dependency. (2006) (26)
- Systematic genomic and translational efficiency studies of uveal melanoma (2017) (26)
- Insertional mutagenesis by a modified in vitro Ty1 transposition system. (1997) (26)
- Bidirectional cross talk between patient‐derived melanoma and cancer‐associated fibroblasts promotes invasion and proliferation (2016) (25)
- A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma. (2019) (25)
- Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer (2016) (24)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer (2019) (20)
- A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC). (2013) (20)
- Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER+ Breast Cancers with a KRAS Mutation or FGFR1 Gene Amplification (2012) (20)
- Whole-genome sequencing and cancer therapy: is too much ever enough? (2012) (19)
- Erratum: Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine (American Journal of Human Genetics (2016) 98(6) (1067–1076) (S0002929716301069) (10.1016/j.ajhg.2016.04.011)) (2016) (17)
- A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine (2016) (17)
- Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor. (2013) (16)
- Identification of genes by functional complementation in protozoan parasite Leishmania (1994) (16)
- The fuzzy world of precision medicine: deliberations of a precision medicine tumor board (2016) (15)
- Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors (2015) (14)
- Integrative Clinical Genomics of Advanced Prostate Cancer Graphical (2015) (14)
- Metabolomic correlates of response in nivolumab-treated renal cell carcinoma and melanoma patients. (2017) (14)
- 6-Phosphogluconate Dehydrogenase Links Cytosolic Carbohydrate Metabolism to Protein Secretion (2018) (13)
- Lineage dependency and lineage-survival oncogenes in human cancer (2006) (13)
- Abstract S1-01: Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer (2017) (13)
- Approaches to carrier testing and results disclosure in translational genomics research: The clinical sequencing exploratory research consortium experience (2018) (13)
- Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma (2019) (12)
- CD38 in Advanced Prostate Cancers (2021) (12)
- Concordance and discordance in tumor genomic profiling. (2012) (11)
- Stepwise-edited, human melanoma models reveal mutations’ effect on tumor and microenvironment (2022) (11)
- Isolation of virulence genes directing GPI synthesis by functional complementation of Leishmania. (1994) (10)
- Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). (2018) (10)
- An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. (2022) (10)
- Array-based approaches to cancer genome analysis (2005) (9)
- Abstract 3933: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling (2011) (9)
- FGFR 3 expression in primary and metastatic urothelial carcinoma of the bladder (2014) (8)
- An Oncogenic Role for ETV 1 in Melanoma (2010) (7)
- Erratum: Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays (PLoS Computational Biology 2, 5, doi:10.1371/journal.pcbi.0020041) (2007) (7)
- Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer (2007) (7)
- Mechanisms of Resistance to Mitogen-Activated Protein Kinase Pathway Inhibition in BRAF-Mutant Melanoma. (2012) (7)
- Prediction of drug response using genomic signatures from the Cancer Cell Line Encyclopedia (2010) (7)
- Erratum: High-throughput oncogene mutation profiling in human cancer (Nature Genetics (2007) 39, (347-351)) (2007) (7)
- Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. (2016) (7)
- Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones (2012) (6)
- PROFILE: Broadly based genomic testing for all patients at a major cancer center. (2013) (6)
- Comprehensive molecular characterization of colorectal cancer reveals genomic predictors of immune cell infiltrates. (2015) (6)
- Analysis of tumor mutation burden (TMB) in >51,000 clinical cancer patients to identify novel non-coding PMS2 promoter mutations associated with increased TMB. (2016) (6)
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden (2017) (6)
- Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes. (2013) (6)
- BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. (2015) (6)
- Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 (2015) (6)
- Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2020) (5)
- Publisher Correction: The long tail of oncogenic drivers in prostate cancer (2019) (5)
- Abstract 5455: Integrative analysis of the Cancer Cell Line Encyclopedia reveals genetic and transcriptional predictors of compound sensitivity (2011) (5)
- Williams sneak attacks Instantaneous energetics of puma kills reveal advantage of felid (2014) (5)
- Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003. (2014) (5)
- A Notch for noncoding RNA in melanoma. (2014) (5)
- Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition. (2013) (4)
- Molecular biology of cutaneous melanoma (2015) (4)
- Erratum for the research article: Genomic proling of ER + breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance (Science Translational Medicine DOI: 10.1126/scitranslmed.aai7993) (2019) (4)
- Increased Local Disorder of DNA Methylation Forms the Basis of High Intra-Leukemic Epigenetic Heterogeneity and Enhances CLL Evolution (2013) (4)
- Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (4)
- Defining a molecular subclass of treatment resistant prostate cancer. (2015) (4)
- Abstract C72: Combined pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors (2015) (4)
- The genetic landscape of clinical resistance to RAF inhibition in melanoma. (2013) (4)
- Abstract 3152: CanSeq: prospective clinical whole-exome sequencing of FFPE tumor samples. (2013) (3)
- Abstract CN07-04: Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq (2015) (3)
- A heuristic platform for clinical interpretation of cancer genome sequencing data. (2012) (3)
- Making cancer research more inclusive (2021) (3)
- Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity (2018) (3)
- Somatic alterations in the PTEN-PI3K-AKT-mTOR pathway in a cohort of 379 ovarian cancer patients. (2016) (3)
- Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) (2020) (3)
- Cell-free tumor DNA and TERT promoter mutations in bladder cancer. (2017) (2)
- ERRATUM: Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium (2014) (2)
- Distinct genetic profiles of extracranial and intracranial acral melanoma metastases (2016) (2)
- Abstract PR10: A cyclic AMP-regulated melanocyte lineage program confers resistance to MAP kinase pathway inhibition (2013) (2)
- Molecular Genetics of Melanocytic Neoplasia (2018) (2)
- Abstract 4565: Whole exome sequencing links MAPK1 mutation to exquisite sensitivity to brief erlotinib monotherapy in head and neck cancer. (2013) (2)
- Remember why we work on cancer (2017) (2)
- Inferring Loss-of-Heterozygosity From Tumor-only Samples Using High-Density Oligonucleotide SNP Arrays (2)
- Inherited mutations in DNA repair genes in men with metastatic castration-resistant prostate cancer. (2016) (2)
- Abstract 3576: Broad analysis of recurrent somatic mutations in cancer reveals a common novel non-coding mutation in the promoter of PMS2 associated with greatly increased tumor mutation load (2016) (2)
- On or Off Target: Mutations, Models, and Predictions (2010) (2)
- Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity (2012) (2)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade. (2018) (1)
- Abstract PR04: A melanoma transcriptional state distinction influences sensitivity to MAPK pathway inhibitors (2015) (1)
- Transgenerational genomic effect of chemotherapy exposure in testicular cancer survivors. (2015) (1)
- Integrative analysis of the melanoma transcriptome Material Supplemental (2010) (1)
- Abstract 5759: The landscape of copy-number changes across multiple human cancer types (2010) (1)
- Abstract 3036: Real-time genomic characterization of metastatic pancreatic cancer to enable precision medicine (2017) (1)
- Abstract 3037: Dissecting treatment resistance in patients with ovarian cancer and PDX-models using single-cell RNA-sequencing (2017) (1)
- Polymorphism Array Analysis Human Lung Carcinomas Revealed by Single Nucleotide Homozygous Deletions and Chromosome Amplifications in (2005) (1)
- Abstract PR02: Towards a Cancer Dependency Map (2017) (1)
- Deliberations of a precision medicine tumor board. (2016) (1)
- Enrichment of germline DNA-repair gene mutations in patients with colorectal cancer. (2017) (1)
- Supplementary Material 10 (2014) (1)
- Abstract 105: Integrative analysis of genomic and pharmacologic data from the Cancer Cell Line Encyclopedia (2010) (1)
- Characterizing reduced coverage regions through comparison of exome and genome sequencing data across 10 centers (2017) (1)
- Abstract PD6-3: Recurrent ESR1 fusion transcripts are associated with endocrine resistance in estrogen receptor positive, HER2 negative breast cancer (2015) (1)
- Abstract B70: Conexic: A Bayesian framework to detect drivers and their function uncovers an endosomal signature in melanoma (2009) (1)
- Unraveling the clonal hierarchy of somatic genomic aberrations (2014) (1)
- Abstract P3-05-09: Exploring bazedoxifene and palbociclib as potential therapeutic strategies for overcoming ESR1-mediated endocrine resistance (2016) (1)
- Abstract AP19: SINGLE–CELL RNA–SEQUENCING OF PATIENT–DERIVED OVARIAN CANCER CELLS AND PATIENT–DERIVED XENOGRAFT MODELS (2017) (1)
- Highly multiplexed quantitative phosphosite assay for biology and preclinical studies (2020) (1)
- Believe the miracles: of biomedical science and human suffering. (2016) (1)
- Abstract NG04: Clinical acquired resistance to RAF inhibitor combinations in BRAF mutant colorectal cancer through MAPK pathway alterations (2015) (1)
- Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC). (2015) (1)
- Stepping on the GAS: a brake pedal for melanoma metastasis? (2009) (1)
- Re: Stoehr et al. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. J Pathol 2013; 230: 453–456 (2013) (1)
- Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. (2022) (1)
- The long tail of oncogenic drivers in prostate cancer (2018) (1)
- Abstract P3-05-13: Estrogen-independent growth ofESR1-mutant breast cancer cells requires CDK4/6 (2016) (1)
- Tumor genomic profiling of FFPE samples by massively parallel sequencing. (2011) (1)
- Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns (2020) (1)
- A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer. (2016) (1)
- Abstract 1806: TRIM24 is an oncogenic transcriptional activator in prostate cancer (2016) (1)
- Abstract 4380: Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-sequencing (2016) (1)
- Cancer patients' preferences for return of somatic and germline whole-exome sequencing results: Data from the CANSEQ study. (2014) (1)
- Abstract 3431: Functional characterization of ARID2 in melanoma and melanocytes (2014) (1)
- Abstract 4017: Dissecting the clonal hierarchy of cancer-driving genomic lesions. (2013) (1)
- The Genomic Architecture of Prostate Cancer (2014) (1)
- The long tail of significantly mutated genes in prostate cancer. (2017) (1)
- Inclusion of the ASH1 gene that governs the neuroendocrine differentiation of lung epithelium as an additional prototypic 'lineage-survival oncogene' (2007) (1)
- Malignant Melanoma Modeling Genomic Diversity and Tumor Dependency in Updated (2008) (1)
- Abstract 2570: An integrated germline analysis platform for comprehensive clinical cancer genomics. (2013) (1)
- Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) using whole exome sequencing (WES) (2019) (1)
- Abstract #3822: PDK1-SGK3 signaling in the absence of AKT activation in PIK3CA- mutant cancers (2009) (1)
- Abstract 2011: The PI3K pathway is the most frequently mutated mitogenic pathway in HNSCC. (2013) (1)
- Abstract 5221: Linking the molecular profile of colorectal tumors to germline genetic and environmental risk factors (2016) (1)
- Abstract 2620: The Cancer Cell Line Encyclopedia project: From integrative cancer genomics to personalized cancer therapy (2010) (0)
- Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER (2019) (0)
- Abstract B33: Integration of genome-wide datasets identifies SOX10 as a lineage-specific genetic dependency in melanoma (2015) (0)
- Abstract B44: Emerging targets from Cancer Dependency Map v0.1 (2017) (0)
- Correction: Inferring Loss-of-Heterozygosity from Unpaired Tumors Using High-Density Oligonucleotide SNP Arrays (2007) (0)
- SNP array based analyses of somatic genetic and the identification of MITF as a lineage survival oncogene amplified in malignant melanoma (0)
- Abstract B108: A genome-scale shRNA synthetic lethal screen identifies enhancers of sensitivity to RAF inhibition. (2013) (0)
- High-throughput oncogene mutation detection in human cancers by mass spectrometry-based genotyping (2006) (0)
- Abstract PR02: Identification of ERK1/2 mutations that confer resistance to MAPK pathway inhibitors (2015) (0)
- Title: Genomic heterogeneity and exceptional response to dual pathway inhibition in anaplastic thyroid cancer Authors: (2016) (0)
- AKT-independent, PDK1-dependent signaling by oncogenic PIK3CA mutations (2008) (0)
- Dooley 1 Nuclear Factor I / B is an Oncogene in Small Cell Lung Cancer (2011) (0)
- Abstract B18: High-dimensional combinations of cancer drugs to induce synthetic lethality in colorectal cancer (2013) (0)
- Abstract 3254: Dissecting genomic determinants of response to platinum-based chemotherapy in advanced NSCLC and colorectal cancer (2018) (0)
- hi gh-t h roughput Detection of ac tionable Genomic al terations in cl inical t u mor s a mples by t a rgeted, Massively Parallel s e quencing (2012) (0)
- Abstract B15: Comprehensive cistromic characterization of SOX10, a lineage-specific genetic dependency in melanoma, via the integration of functional genomic approaches (2017) (0)
- A Functional Landscape o f Resistance to ALK Inhibition in Lung Cancer Graphical Abstract Highlights (2015) (0)
- Abstract 95: Somatic mutations and copy number variations in cancer-associated genes in 695 ovarian cancer patients (2016) (0)
- Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors (2017) (0)
- Abstract LB-113: MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability inBRAF,NRASandNF1-mutant melanomas (2019) (0)
- Miniaturizing 3D assay for high-throughput drug and genetic screens for small patient-derived tumor samples (Conference Presentation) (2017) (0)
- Abstract B39: Genomic copy number alterations introduce a gene-independent viability bias in CRISPR-Cas9 knock-out screens of cancer cell lines (2017) (0)
- Abstract B17: Identification of Druggable Targets through Functional Multi-Omics in Renal Medullary Carcinoma (2017) (0)
- Abstract LB-B04: Complex drug combinations can induce apoptotic killing in robust colorectal cancer cells (2015) (0)
- Epigenomic Alterations in Localized and Advanced (2013) (0)
- Phenotypic Characterizati on of a Comprehensive Set of MAPK 1 / ERK 2 Missense Mutants Graphical (2016) (0)
- Opposing therapeutic efficacy of BET inhibitors is determined by cancer type-specific SPOP mutants (2016) (0)
- Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer (2016) (0)
- the of cancer and proteomic data across tumor types. (2016) (0)
- Abstract A02: Expanding tumor chemical-genetic interaction map using next-generation cancer models (2017) (0)
- Supplemental Information Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia (2014) (0)
- Publisher Correction: The long tail of oncogenic drivers in prostate cancer (2019) (0)
- Abstract PR5: Identifying mechanisms of drug resistance to MAPK pathway inhibition via genome-scale rescue screens (2012) (0)
- Abstract 571: Meta-analysis of genomic predictors of response to immune checkpoint therapy in metastatic melanoma (2017) (0)
- Abstract 3925: Characterization of complex chromosomal aberrations in prostate cancer from whole genome sequencing (2011) (0)
- Abstract 2953: Anticipating new biochemical mechanisms of resistance to Raf inhibition in Melanoma (2012) (0)
- Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer (2014) (0)
- From Genomic Diversity to Tumor Dependency in Human Cancer (2007) (0)
- High Resolution SNP Arrays Identify Amplified Regions in Lung Cancer (2005) (0)
- Abstract B27: Probing synthetic lethal interactions with RAF inhibition in BRAF-mutant colorectal cancer (2013) (0)
- Abstract PR4: Integrative analysis of genomic and pharmacologic data from the Cancer Cell Line Encyclopedia (2010) (0)
- Abstract C221: A genome-wide RNA interference screen identifies synthetic lethal interactions with the BRAF oncogene. (2013) (0)
- Abstract LB-228: The identification of recurrent non-coding mutations in melanoma. (2013) (0)
- Abstract 1564: A computational framework for removing mouse contamination in tumors sequenced from patient-derived xenografts (2017) (0)
- Abstract 1311: High order drug combinations are required to effectively kill colorectal cancer cells (2016) (0)
- Abstract 1010: Genomic analysis of recurrent ovarian cancer in patient-derived xenografts treated with platinum and taxane chemotherapy (2017) (0)
- Abstract SY05-03: Dissecting genomic correlates of response and resistance to chemotherapy in bladder cancer through clinical computational oncology (2019) (0)
- Inferring Loss-of-Heterozygosity from Tumors Without Paired Normals Using High-Density SNP Arrays (2005) (0)
- Resource Integrative Clinical Genomics of Advanced Prostate Cancer (2016) (0)
- Abstract 4819: Differential evolution of tumor heterogeneity in leiomyosarcomas and liposarcomas suggested by genomic profiling (2015) (0)
- Abstract SY45-04: Development of therapeutic strategies by resolving the tumor ecosystem (2019) (0)
- The landscape of cancer cell line metabolism (2019) (0)
- 1314 RECURRENT MUTATIONS IN SPOP DEFINE A DISTINCT MOLECULAR CLASS OF PROSTATE CANCER (2012) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- Abstract PR04: mTOR mutations in cancer (2015) (0)
- Abstract 1286: Targeted deep sequencing of colorectal tumor tissues to study associations of tumor subtypes with germline genetic, lifestyle, and environmental risk factors (2017) (0)
- Abstract B38: Developing a functional genomics platform to interrogate rare pediatric cancers (2016) (0)
- Abstract 3931: Whole genome and whole exome sequencing of head and neck cancer (2011) (0)
- Isolation ofvirulence genesdirecting surface glycosyl- phosphatidylinositol synthesis byfunctional complementation (1993) (0)
- Performance of genomic data strategies for cancer precision medicine across distinct contexts and ethnicities. (2016) (0)
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2019) (0)
- 062 Human melanoma TILs share phenotypic and transcriptional properties with tissue resident memory T cells (2017) (0)
- Abstract 136: Refining the molecular profile of colorectal tumors to expand prevention and treatment opportunities (2016) (0)
- Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2020) (0)
- Next-generation characterization of the Cancer Cell Line Encyclopedia (2019) (0)
- 065 Highly conserved tissue immune signatures are co-opted in cancer (2017) (0)
- Abstract PR01:Fusobacterium nucleatumand mutational landscape of colorectal cancer in whole-exome sequencing analysis (2017) (0)
- The Genomic Landscape of Prostate Cancer this this you. Your (2012) (0)
- Abstract 957: Towards precision functional genomics via next-generation functional mapping of cancer variants (2015) (0)
- Abstract 923: Separating the wheat from the chaff: A first look at the Cancer Cell Lines Encyclopedia sequencing data (2011) (0)
- Abstract 1953: Accelerating prediction of pediatric and rare cancer vulnerabilities using next-generation cancer models (2017) (0)
- Spotlight on Clinical Response Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER þ Breast Cancers with a KRAS Mutation or FGFR 1 Gene Ampli fi cation (2012) (0)
- Abstract 3111: The ETS factor ETV1 is an oncogene in melanoma (2010) (0)
- Abstract 5647: Intron retention as a novel source of tumor neoantigens associated with response to checkpoint inhibitor therapy (2017) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- Abstract 1139: Complete characterization of prostate cancer genomes by massively parallel sequencing (2010) (0)
- Abstract 1073: A systematic approach to identify the Ras-dependent C-RAF(Ser338)-phosphorylating kinase (2011) (0)
- Abstract LB-249: Oncogene-mediated alterations in chromatin conformation (2011) (0)
- Abstract SY17-02: A systems approach to understanding tumor specific drug response (2011) (0)
- 200 DEFINING THE MECHANISTIC BASIS OF SPOP MUTATIONS IN PROSTATE CANCER (2013) (0)
- Abstract 5769: A novel, high-throughput approach to discovering drug-resistance genes identifies CRAF, CrkL, and TPL2/COT as drivers of resistance to BRAFV600E inhibition (2010) (0)
- Somatic cancer mutations across populations (2007) (0)
- Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer (2017) (0)
- Mechanisms of resistance (MoR) to DNA damaging therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer (MBC). (2016) (0)
- Abstract 4601: Punctuated evolution of prostate cancer genomes. (2013) (0)
- Synthetic lethality as an engine for cancer drug target discovery (2019) (0)
- Abstract 5114: Integrative analysis of the Cancer Cell Line Encyclopedia reveals genetic and transcriptional predictors of compound sensitivity (2012) (0)
- Abstract A082: Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance (2019) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- Clinical actionability of germline testing in patients with limited colorectal polyps. (2017) (0)
- Assigning clinical meaning to somatic and germline whole exome sequencing data to guide cancer precision medicine. (2016) (0)
- Abstract PR01: Global chromatin profiling identifies NSD2 mutations in pediatric acute lymphoblastic leukemia (2013) (0)
- Abstract C070: REAL variance in genomic testing by sex, age, race, ethnicity, and language: PROFILE database 7/2011 - 1/2022 (2023) (0)
- Abstract LB-246: Recurrent inactivating mutations in SPOP define a molecular subset of prostate cancer (2011) (0)
- S3-4: ER Downregulation with Fulvestrant in Combination with pan-PI3K Inhibitor BKM120 Synergizes Against ER+/PI3K-Mutant Breast Cancer Xenografts In Vivo. (2011) (0)
- Rapid IntraoperativeMolecular Characterization of Glioma (2015) (0)
- Abstract 819: Targeted sequencing to detect somatic mutations, translocations and copy-number variation in human tumors simultaneously. (2013) (0)
- Correction: Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples (2009) (0)
- Abstract IA13: Recurrent SPOP mutations define a distinct molecular subclass of prostate cancer (2012) (0)
- Abstract 2371: Heterogeneity of resistance mechanisms in lung adenocarcinoma patients with acquired resistance to EGFR inhibitors (2014) (0)
- Abstract 3566: The long tail of significantly mutated genes in prostate cancer (2017) (0)
- Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014. (2015) (0)
- Abstract PR05: Genome-scale CRISPR-Cas9 screening to identify essential genes and pathways in pancreatic cancer (2016) (0)
- Abstract 2150: Alternative treatment strategies to overcome MAPK inhibitor resistance in melanoma (2016) (0)
- Abstract A23: An integrated platform for the functional annotation of the cancer genome (2009) (0)
- Abstract 5561: Single-cell analysis reveals an adaptive, transiently heritable, slowly-dividing, drug-resistant state inhibitable by drug combinations (2017) (0)
- Theurillat in SPOP-mutant prostate cancer Ubiquitylome analysis identifies dysregulation of effector substrates (2014) (0)
- Abstract 2930: Global chromatin profiling reveals NSD2 mutation in pediatric ALL (2014) (0)
- Abstract 1724: Genomic mechanisms of exquisite sensitivity and acquired resistance to everolimus in a patient with anaplastic thyroid carcinoma (2014) (0)
- Correction: Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples (2009) (0)
- Abstract 3965: An algorithm to detect somatic mutations in cancer specimens using mass spectrometric genotyping (2012) (0)
- Abstract 13: Chemical genomics identifies MCL1 repressors and resistance mechanism (2011) (0)
- Label-free longitudinal monitoring of melanogenesis in the evolution of melanoma treatment resistance (Conference Presentation) (2017) (0)
- Implementation of a prostate cancer‐specific targeted sequencing panel for credentialing of patient‐derived cell lines and genomic characterization of patient samples (2022) (0)
- Abstract PR17: Single-cell analysis reveals an adaptive, slowly-dividing, de-differentiated, drug-resistant cell state selectively inhibitable by drug combinations (2017) (0)
- Study of genetic alterations in soft tissue sarcomas by SNP arrays, expression profiling and high-throughput sequencing (2007) (0)
- Abstract PL07-01: Molecular profiling of breast cancer in Mexico: Identification of novel therapeutic targets through whole genome sequencing analysis. (2012) (0)
- Molecular determinants of resistance to CDK4/6 inhibition in ER+ breast cancer (2016) (0)
- Abstract 4367: Accelerating prediction of tumor vulnerabilities using next-generation cancer models (2016) (0)
- Abstract P3-06-11: Understanding resistance mechanisms of PIK3a inhibition in breast cancer (2016) (0)
- Abstract PR07: Towards precision functional genomics via next-generation functional mapping of cancer variants (2015) (0)
- Abstract B26: Accelerating prediction of tumor vulnerabilities using next-generation cancer models (2016) (0)
- 608 COMBINING DNA-SEQ AND RNA-SEQ FOR DISCOVERY OF NOVEL MUTATIONS IN HUMAN PROSTATE CANCER (2011) (0)
- Whole‐exome sequencing analyses of colorectal cancer with Fusobacterium nucleatum (2017) (0)
- Abstract MIP-075: SOMATIC MUTATIONS AND COPY-NUMBER VARIATIONS IN OVARIAN CANCERS VIA TARGETED SEQUENCING OF EXONS OF 300 CANCER-ASSOCIATED GENES, INCLUDING MULTIPLE DNA DAMAGE REPAIR GENES (2017) (0)
- Novel driver genes and genomic predictors of immune infiltrates in colorectal cancer. (2016) (0)
- Abstract B23: Genomic sequencing of metastatic hormone-receptor positive breast cancer implicates AKT1 in driving resistance to cyclin-dependent kinase 4/6 inhibitors (2020) (0)
- Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations (2017) (0)
- Abstract 3693: Small molecule microarray screens for inhibitors of oncogenic ETS factors (2010) (0)
- Abstract LB-227: Truncal activating MAPK and PI3K pathway alterations and exceptional response to dual pathway inhibition in anaplastic thyroid cancer (2016) (0)
- Supplementary Material 8 (2013) (0)
- Abstract 1224: Deep targeted tumor sequencing of colorectal cancer cases to study associations of molecular subtypes with clinical, genetic, and lifestyle risk factors (2018) (0)
- LG-47TYPE II RAF INHIBITORS INHIBIT BRAF MUTATIONS AND TRUNCATED FUSIONS IN PEDIATRIC LOW-GRADE GLIOMAS (2016) (0)
- Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade (2020) (0)
- Abstract A1-15: Systematic genomic characterization of uveal melanoma (2015) (0)
- Abstract PR18: Somatic ERCC2 mutations, nucleotide excision repair (NER) function, and cisplatin response in muscle-invasive bladder cancer (MIBC) (2017) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- Abstract LB-122: High-throughput tumor genomic profiling by massively parallel sequencing (2010) (0)
- 037 A systems immunology approach to classify melanoma tumor infiltrating lymphocytes (TILs) informs and models overall survival (2022) (0)
- Abstract LB-018: Defining a molecular subclass of treatment-resistant prostate cancer (2015) (0)
- Abstract 237: Enrichment of AXL-high/ MITF-low melanoma cells in the presence of MAPK inhibitorsin vitro (2016) (0)
- Abstract 4727: Genomic characterization of brain metastases reveals divergent evolution and metastasis specific mutations (2015) (0)
- Abstract 3429: Synthetic lethal RNAi screens to nominate potential therapeutic combinations for uveal melanoma (2014) (0)
- Implementation of single-cell genomics as a translational tool in patients with metastatic melanoma. (2016) (0)
- Abstract B20: A genome-scale RNA interference screen for resistance mechanisms to BRAF inhibition in melanoma (2012) (0)
- Abstract 600: Melanoma and ovarian cancer cells tested for drug sensitivity using anchorage-independent growth (2016) (0)
- 428 Clinical acquired resistance to combined RAF/EGFR or RAF/MEK inhibition in BRAF mutant colorectal cancer (CRC) patients through MAPK pathway alterations (2014) (0)
- Safety of bevacizumab in patients with glioblastoma multiforme ( GBM ) : a single institution ’ s experience (2011) (0)
- The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine (2016) (0)
- Abstract 5056: A glimpse into the somatic mutation landscape of melanoma through exome sequencing of 121 tumor-normal pairs (2012) (0)
- Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Levi Alexander Garraway?
Levi Alexander Garraway is affiliated with the following schools: